PE20100746A1 - Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables - Google Patents
Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradablesInfo
- Publication number
- PE20100746A1 PE20100746A1 PE2009001300A PE2009001300A PE20100746A1 PE 20100746 A1 PE20100746 A1 PE 20100746A1 PE 2009001300 A PE2009001300 A PE 2009001300A PE 2009001300 A PE2009001300 A PE 2009001300A PE 20100746 A1 PE20100746 A1 PE 20100746A1
- Authority
- PE
- Peru
- Prior art keywords
- camptotechin
- biocompatible
- biodegradable
- pharmaceutical formulations
- polymer conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTOS DE FORMULA I, DONDE R1 ES H, -C(O)-CH2-CH2-C(O)-OH Y EL OTRO ES -CO-CH2-CH2-C(O)-NH-CH2-C(O)-OCPT; R2 ES H, -C(O)-CH2-CH2-C(O)-OH; CPT ES CAMPTOTECINA; n ES 32-3320; m ES 0-833; k ES 1-216, DONDE k, m Y n SE SELECCIONAN DE MODO TAL QUE APROXIMADAMENTE 1-15% DEL COMPUESTO EN PESO ES CAMPTOTECINA; B) UN AGENTE DE ESTABILIZACION SELECCIONADO ENTRE SORBITOL, MANITOL, SACAROSA, LACTOSA, GLUCOSA, XILITOL, ENTRE OTROS; C) UNO O VARIOS TAMPONES SELECCIONADOS ENTRE CITRATO DE SODIO, ASCORBATO, GLICINA, EDTA, 3-(N-MORFOLINO)PROPANSULFONICO; D) UN TENSIOACTIVO SELECCIONADO ENTRE POLISORBATO 80, POLOXAMER 407, SOLUTOL HS 15, CLORURO DE BENZALCONIO. DICHA FORMULACION ES UNA TORTA LIOFILIZADA APROPIADA PARA ADMINISTRACION ENDOVENOSA UTIL EN EL TRATAMIENTO ANTINEOPLASICO Y ANTITUMORAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12138408P | 2008-12-10 | 2008-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20100746A1 true PE20100746A1 (es) | 2010-11-04 |
Family
ID=42243068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2009001300A PE20100746A1 (es) | 2008-12-10 | 2009-12-10 | Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables |
Country Status (9)
Country | Link |
---|---|
US (2) | US8491880B2 (es) |
KR (1) | KR20110102420A (es) |
CN (1) | CN102307473A (es) |
AR (1) | AR074584A1 (es) |
CL (1) | CL2009002167A1 (es) |
PA (1) | PA8853201A1 (es) |
PE (1) | PE20100746A1 (es) |
TW (1) | TW201036639A (es) |
WO (1) | WO2010068759A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013528665A (ja) * | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
US20180157397A1 (en) * | 2016-04-08 | 2018-06-07 | Maxx Media Group, LLC | System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display |
CN109563215B (zh) * | 2016-06-03 | 2021-11-19 | 诺灵生物医药科技(北京)有限公司 | 聚合物连接子及其用途 |
CA3041254A1 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Cd43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
EP3802580A1 (en) | 2018-06-05 | 2021-04-14 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4793986A (en) | 1987-02-25 | 1988-12-27 | Johnson Matthey, Inc. | Macromolecular platinum antitumor compounds |
JPH01190636A (ja) | 1988-01-22 | 1989-07-31 | Green Cross Corp:The | 制癌作用物質複合体 |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
EP0654973A4 (en) | 1992-07-21 | 1995-08-09 | Gen Hospital Corp | LYPHATIC TISSUE DRUG ADMINISTRATION SYSTEM. |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5612037A (en) | 1994-07-26 | 1997-03-18 | Connaught Laboratories, Inc. | Influenza virus subunit conjugates |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6048837A (en) | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
WO1996030386A1 (fr) | 1995-03-31 | 1996-10-03 | Drug Delivery System Institute, Ltd. | Derives d'amidite et derives d'oligonucleotides |
US5811510A (en) | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US6818630B1 (en) | 1999-06-18 | 2004-11-16 | Ml Laboratories Plc | Biologically active materials |
IL131074A0 (en) | 1999-07-23 | 2001-03-19 | Polygene Ltd | A biodegradable polycation composition for delivery of an anionic macromolecule |
US6822086B1 (en) | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
JP4813712B2 (ja) | 1999-08-09 | 2011-11-09 | ザ ジェネラル ホスピタル コーポレーション | 薬物−担体複合体およびその使用方法 |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
ES2294026T3 (es) | 2000-09-06 | 2008-04-01 | Ap Pharma, Inc. | Polimeros degradables de poliacetal. |
US7838619B2 (en) | 2002-01-14 | 2010-11-23 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
DE60329126D1 (de) | 2002-02-20 | 2009-10-15 | Beth Israel Hospital | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
AU2003254023A1 (en) | 2002-07-19 | 2004-02-09 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
AU2003256613A1 (en) | 2002-07-19 | 2004-02-09 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
EP2402036B1 (en) | 2002-09-06 | 2018-02-14 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto |
EP1608380A2 (en) | 2003-03-31 | 2005-12-28 | Vectramed, Inc. | Polymeric drug agents for the treatment of fibrotic disorders |
ES2365918T3 (es) | 2003-09-05 | 2011-10-13 | The General Hospital Corporation | Conjugados de poliacetal-fármaco como sistema de liberación. |
EP1547580A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
JP4840449B2 (ja) | 2007-01-31 | 2011-12-21 | 中央電気工業株式会社 | 炭素材料およびその製造方法 |
EA020251B1 (ru) | 2007-11-28 | 2014-09-30 | Мерсана Терапьютикс, Инк. | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина |
WO2010144881A1 (en) | 2009-06-12 | 2010-12-16 | The General Hospital Corporation | Treatment of meningeal and neural diseases |
-
2009
- 2009-12-10 CN CN2009801563966A patent/CN102307473A/zh active Pending
- 2009-12-10 CL CL2009002167A patent/CL2009002167A1/es unknown
- 2009-12-10 TW TW098142264A patent/TW201036639A/zh unknown
- 2009-12-10 KR KR1020117015636A patent/KR20110102420A/ko not_active Application Discontinuation
- 2009-12-10 AR ARP090104793A patent/AR074584A1/es unknown
- 2009-12-10 PE PE2009001300A patent/PE20100746A1/es not_active Application Discontinuation
- 2009-12-10 US US12/635,027 patent/US8491880B2/en not_active Expired - Fee Related
- 2009-12-10 PA PA20098853201A patent/PA8853201A1/es unknown
- 2009-12-10 WO PCT/US2009/067505 patent/WO2010068759A1/en active Application Filing
-
2013
- 2013-06-18 US US13/920,749 patent/US20140004074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201036639A (en) | 2010-10-16 |
US8491880B2 (en) | 2013-07-23 |
CN102307473A (zh) | 2012-01-04 |
CL2009002167A1 (es) | 2010-10-15 |
US20100179181A1 (en) | 2010-07-15 |
KR20110102420A (ko) | 2011-09-16 |
AR074584A1 (es) | 2011-01-26 |
PA8853201A1 (es) | 2010-07-27 |
US20140004074A1 (en) | 2014-01-02 |
WO2010068759A1 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20100746A1 (es) | Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables | |
ECSP088240A (es) | Composición de trazodona para administración una vez por día | |
AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
PE20060464A1 (es) | Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales | |
AR108936A2 (es) | Formulación subcutánea de anticuerpo anti-her2 | |
AR056609A1 (es) | Composiciones estabilizadas de carbonato de lantano | |
AR092470A1 (es) | Formulaciones acuosas estables de adalimumab | |
PE20050175A1 (es) | Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad | |
ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
HRP20110444T1 (hr) | Formulacije paratiroidnih hormona i njihove uporabe | |
AR059113A1 (es) | Composicion para administracion topica | |
PE20070210A1 (es) | Compuestos macrociclicos como inhibidores del virus de hepatitis c | |
PE20040499A1 (es) | Nuevas formulaciones de liberacion prolongada inyectables | |
ECSP105163A (es) | Composiciones farmaceuticas de agonista parcial de 5ht4 | |
EP2588116A4 (en) | FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN | |
BR9810320A (pt) | Composição farmacêutica sólida, contendo derivados de benzofurano | |
AR106776A1 (es) | Composiciones de cuidado oral | |
NZ593190A (en) | Factor viii formulations | |
PE20061077A1 (es) | Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina | |
ECSP066808A (es) | Solución oftálmica que comprende carboximetilcelulosa de sodio e hidroxipropilmetilcelulosa | |
AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
PE20091715A1 (es) | Variantes de igf-i pegiladas y composiciones que las contienen | |
PE20080153A1 (es) | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) | |
ECSP077262A (es) | Composicion antihistaminica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |